Current Market Access to Avsola, Inflectra and Remicade

While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.

NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/12/21.

AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop
November 16

Third-Quarter 2023 Digital Health Funding, Deals Decline, but Promising Areas Exist

Read More
woman-in-pain
November 16

FDA Approves Multiple Ulcerative Colitis Agents, Bringing New Drugs, Routes of Administration to Class

Read More
scientist-in-a-lab
November 16

Biosimilar Market Has Had Tremendous Year, With No Signs of Slowing

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today